Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-apamistamab Conditioning for Stem Cell Transplant in Severe Sickle Cell Disease
NCT07015684Phase 1Recruiting
- Sponsor
- Columbia University
- Start
- Apr 2025
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apamistamab in sickle cell disease (SCD), sponsored by Columbia University. Primary endpoint: Graft failure rate at 42 days. Started Apr 2025; status: recruiting.
02
Drugs
apamistamab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07015684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015684.